On target, off-tumor side effects with GPRC5D-targeting BsAb therapy
| . | Talquetamab 400 µg/kg SC weekly (n = 30)30 . | Talquetamab 800 µg/kg SC biweekly (n = 44)30 . | Forimtamig SC (n = 57)31 . | |||
|---|---|---|---|---|---|---|
| . | grade 1-2 . | grade 3-4 . | grade 1-2 . | grade 3-4 . | grade 1-2 . | grade 3-4 . |
| Skin-related eventsa | 67 | 0 | 70 | 2 | 82 all grade | 15d |
| Rash-related eventsb | 47 | 0 | 30 | 16 | ||
| Nail-related eventsc | 57 | 0 | 27 | 2 | 22 | 0 |
| Dry mouth | 30 | 0 | 57 | 0 | 74e | 6e |
| Dysgeusia | 63 | NR | 57 | NR | ||
| Dysphagia | 37 | 0 | 27 | 0 | ||
| Decreased appetite | 20 | 3 | 20 | 0 | ||
| Decreased weight | 30 | 0 | 22 | 2 | ||
| . | Talquetamab 400 µg/kg SC weekly (n = 30)30 . | Talquetamab 800 µg/kg SC biweekly (n = 44)30 . | Forimtamig SC (n = 57)31 . | |||
|---|---|---|---|---|---|---|
| . | grade 1-2 . | grade 3-4 . | grade 1-2 . | grade 3-4 . | grade 1-2 . | grade 3-4 . |
| Skin-related eventsa | 67 | 0 | 70 | 2 | 82 all grade | 15d |
| Rash-related eventsb | 47 | 0 | 30 | 16 | ||
| Nail-related eventsc | 57 | 0 | 27 | 2 | 22 | 0 |
| Dry mouth | 30 | 0 | 57 | 0 | 74e | 6e |
| Dysgeusia | 63 | NR | 57 | NR | ||
| Dysphagia | 37 | 0 | 27 | 0 | ||
| Decreased appetite | 20 | 3 | 20 | 0 | ||
| Decreased weight | 30 | 0 | 22 | 2 | ||
Skin-related events included asteatotic eczema, dry skin, eczema, pruritus, exfoliation, fissures, hyperpigmentation, lesions, skin toxic effects, and ulcers.
Rash-related events included contact dermatitis, dermatitis, erythematous rash, generalized exfoliative dermatitis, maculopapular rash, and rash.
Nail-related events included nail-bed disorder, discoloration, dystrophy, hypertrophy, ridging, onycholysis, and onychomadesis.
All skin abnormalities combined.
All oral toxicities combined.
NR, not reported.